Almac Collaborating with Oxford University to Develop Gene Signature for Ductal Carcinoma Recurrence

Aug 08, 2007

NEW YORK (GenomeWeb News) - Cancer diagnostics developer Almac Diagnostics said today it is undertaking a collaborative study with Oxford University that will seek to create a gene signature to predict the recurrence of ductal carcinoma in situ, a type of breast cancer.

The study will use the company’s Breast Cancer DSA microarray to help generate a gene expression signature that would be used to identify patients who are likely to experience a recurrence of DCIS.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Cloud Ready

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

The Science and Policy Connection

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

The New Yeast

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

This Week in Cell

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.

Main menu